Comparison of Oral Anticoagulants for Preventing Stroke in AF

By November 28, 2017

The greatest risk reduction of stroke or systemic embolism was seen with dabigatran 150mg twice daily (odds ratio [OR] 0.65, 95% CI: 0.52-0.81), followed by apixaban 5mg twice daily (OR 0.79, 95% CI: 0.66-0.94).

Victoza Approved to Reduce Risk of MACE

By August 28, 2017

The Food and Drug Administration (FDA) approval was based on data from the randomized, double-blind, placebo-controlled LEADER trial (n=9,340) that evaluated long-term effects of Victoza vs. placebo in patients with type 2 diabetes with high risk of major cardiovascular events (MACE).

Herpes Zoster Tied to Stroke Risk in Patients with Autoimmune Disease

February 03, 2017

For patients with autoimmune disease, herpes zoster tied to increased stroke risk in first 90 days